After an investigation ACM has determined that manufacturer Leadiant abused its dominant position by charging an excessive price for its prescription drug. CDCA-Leadiant. This occurred in the period from June 2017 through December 2019. For this violation ACM has imposed a fine on Leadiant of 19,569,500 euros.
Here you can find the summary of the decision. The public version of the full decision will be published at a later date.